Media Release: 16th December 2021 TGA Rescheduling of Psilocybin and MDMA: Delegate’s Final Decision On December 15th, the Therapeutic Goods Administration (TGA) announced the Delegate’s decision to not
Media Release: 1st of October 2021 TGA Rescheduling of Psilocybin and MDMA Independent Expert Review Panel Report Yesterday, the Australian Therapeutic Goods Administration (TGA) published an Independent Expert Review
Around the world there is a rapidly growing body of scientific evidence suggesting that psychedelic drugs are safe and highly effective when used under medical supervision. Why did promising treatments
Paul Liknaitzky hopes for “rigorous research that is neither biased toward panacea thinking, nor ignorant of the best-practice track record and literature to date”. “This field has suffered from people
Nigel Strauss and Paul Liknaitzky contend that, at least initially, all training should take place within clinical trials overseen by experienced international clinicians and be limited to psychiatrists, psychologists and
While the anecdotal accounts are compelling, significant questions remain around how microdosing works, and how much of the reported benefits are due to pharmacological effects, rather than participants’ beliefs and expectations. Through
People who use drugs understand drugs and drug use in ways that are often different to the way knowledge of drug use is constructed within the dominant medico-legal discourse. Their
There’s a landmark project underway in Melbourne to find out whether psilocybin – the hallucinogenic compound in magic mushrooms – can be used to improve end-of-life experiences. But many Australians
Dr Bright said Australia had the opportunity to “scale up”, with bigger trials ensuring more therapists were trained so when MDMA was given the green light in the US, the
The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support. PRISM supports research and clinical development of therapies where current options provide limited relief.
Your support allows us to pursue cutting edge research for next-generation mental health care.